Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Administer Abasaglar subcutaneously into the abdominal area, thigh, or deltoid.1
Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy.1
Do not dilute or mix Abasaglar with any other insulin or medicinal product as the time/action profile of Abasaglar can be changed and mixing can cause precipitation.1
Do not administer Abasaglar intravenously.1
Pharmacokinetics and Pharmacodynamics
After injection of Abasaglar into the SC tissue, the acidic solution is neutralized, leading to formulation of microprecipitates from which small amounts of Abasaglar are continuously released.1
Abasaglar has a slow and prolonged absorption and a relatively constant concentration/time profile over 24 hours with no pronounced peak.1
There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of insulin glargine.1
1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Glossary
Abasaglar = Abasaglar® (insulin glargine) 100 units/mL
IGlar = insulin glargine
SC = subcutaneous
T1DM = type 1 diabetes mellitus
Datum fӧr senaste ӧversyn 2019 M01 14